Savara Inc. (SVRA)Healthcare | Biotechnology | Langhorne, United States | NasdaqGS
5.78 USD
+0.14
(2.482%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.78 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:19 p.m. EDT
SVRA presents a high-risk, high-reward opportunity due to its biotech sector positioning and recent news about regulatory advancements. However, the lack of dividend history and negative fundamentals suggest it's not a safe bet for long-term investors. Short-term traders might consider the recent momentum and options activity as potential opportunities, but the high volatility and uncertain future earnings make it a speculative play. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.061611 |
| AutoETS | 0.062542 |
| AutoTheta | 0.062543 |
| MSTL | 0.067865 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 73% |
| H-stat | 1.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.415 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.726 |
| Market Cap | 1,182,920,448 |
| Forward P/E | -17.73 |
| Beta | 0.31 |
| Website | https://www.savarapharma.com |
As of April 11, 2026, 4:19 p.m. EDT: Options speculators are showing mixed signals. The calls are positioned with higher open interest and volume on the out-of-the-money strikes, suggesting some bullish sentiment, especially with the upcoming EMA validation and FDA priority review. However, puts are also showing significant open interest on the out-of-the-money strikes, indicating potential bearish sentiment or hedging against downside risk. The overall options activity suggests a cautious outlook with a balance between bullish and bearish expectations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.895082 |
| Address1 | 1,717 Langhorne Newtown Road |
| Address2 | Suite 300 One Summit Square |
| All Time High | 17.187 |
| All Time Low | 0.69 |
| Ask | 5.77 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,310,940 |
| Average Daily Volume3 Month | 1,603,833 |
| Average Volume | 1,603,833 |
| Average Volume10Days | 1,310,940 |
| Beta | 0.313 |
| Bid | 5.74 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 0.802 |
| City | Langhorne |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.78 |
| Current Ratio | 11.846 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.8899 |
| Day Low | 5.67 |
| Debt To Equity | 14.726 |
| Display Name | Savara |
| Dividend Date | 1,493,337,600 |
| Earnings Timestamp | 1,773,405,000 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -122,676,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.248 |
| Enterprise Value | 1,257,149,568 |
| Eps Current Year | -0.46833 |
| Eps Forward | -0.326 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.514 |
| Fifty Day Average Change | 0.26600027 |
| Fifty Day Average Change Percent | 0.048240893 |
| Fifty Two Week Change Percent | 89.5082 |
| Fifty Two Week High | 7.005 |
| Fifty Two Week High Change | -1.2249999 |
| Fifty Two Week High Change Percent | -0.17487507 |
| Fifty Two Week Low | 1.89 |
| Fifty Two Week Low Change | 3.8900003 |
| Fifty Two Week Low Change Percent | 2.0582013 |
| Fifty Two Week Range | 1.89 - 7.005 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,386,200,000 |
| Float Shares | 130,014,911 |
| Forward Eps | -0.326 |
| Forward P E | -17.730062 |
| Free Cashflow | -55,517,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 70 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -81,404,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0233 |
| Held Percent Institutions | 0.97783995 |
| Implied Shares Outstanding | 204,657,500 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania. |
| Long Name | Savara Inc. |
| Market | us_market |
| Market Cap | 1,182,920,448 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_59211637 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -118,837,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,182,920,344 |
| Number Of Analyst Opinions | 8 |
| Open | 5.79 |
| Operating Cashflow | -101,037,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 512 614 1848 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.78 |
| Post Market Time | 1,776,463,538 |
| Previous Close | 5.64 |
| Price Eps Current Year | -12.341725 |
| Price Hint | 2 |
| Price To Book | 7.206983 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.662 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.14 |
| Regular Market Change Percent | 2.48228 |
| Regular Market Day High | 5.8899 |
| Regular Market Day Low | 5.67 |
| Regular Market Day Range | 5.67 - 5.8899 |
| Regular Market Open | 5.79 |
| Regular Market Previous Close | 5.64 |
| Regular Market Price | 5.78 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,686,382 |
| Return On Assets | -0.32908002 |
| Return On Equity | -0.6345 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 204,657,499 |
| Shares Percent Shares Out | 0.134 |
| Shares Short | 27,429,578 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 22,414,290 |
| Short Name | Savara, Inc. |
| Short Percent Of Float | 0.156 |
| Short Ratio | 15.04 |
| Source Interval | 15 |
| State | PA |
| Symbol | SVRA |
| Target High Price | 16.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 10.5625 |
| Target Median Price | 10.0 |
| Total Cash | 236,594,000 |
| Total Cash Per Share | 0.934 |
| Total Debt | 29,914,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.54755 |
| Two Hundred Day Average Change | 1.23245 |
| Two Hundred Day Average Change Percent | 0.27101406 |
| Type Disp | Equity |
| Volume | 1,686,382 |
| Website | https://www.savarapharma.com |
| Zip | 19,047 |